Formula Growth Ltd. Acquires Shares of 5,334 United Therapeutics Corporation $UTHR

Formula Growth Ltd. bought a new position in United Therapeutics Corporation (NASDAQ:UTHR) during the second quarter, Holdings Channel.com reports. The institutional investor bought 5,334 shares of the biotechnology company’s stock, valued at approximately $2,890,000.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Jefferies Financial Group Inc. purchased a new stake in shares of United Therapeutics in the second quarter valued at approximately $3,629,000. Public Employees Retirement System of Ohio purchased a new position in United Therapeutics during the second quarter worth approximately $13,988,000. Capstone Investment Advisors LLC purchased a new position in United Therapeutics during the second quarter worth approximately $608,000. Redwood Investment Management LLC acquired a new position in United Therapeutics during the second quarter worth $1,167,000. Finally, Proficio Capital Partners LLC acquired a new position in United Therapeutics during the second quarter worth $438,000. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts have issued reports on the company. JPMorgan Chase & Co. upped their target price on United Therapeutics from $685.00 to $687.00 and gave the company an “overweight” rating in a report on Thursday, July 23rd. Royal Bank Of Canada lowered their price target on shares of United Therapeutics from $704.00 to $677.00 and set an “outperform” rating on the stock in a research report on Thursday, August 6th. Morgan Stanley set a $515.00 price objective on shares of United Therapeutics in a report on Thursday, August 6th. TD Cowen restated a “buy” rating on shares of United Therapeutics in a research report on Thursday, May 21st. Finally, Weiss Ratings raised shares of United Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a research note on Thursday, August 13th. Eleven analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat, United Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $646.00.

Insiders Place Their Bets

In related news, CEO Martine A. Rothblatt sold 9,500 shares of the business’s stock in a transaction on Wednesday, August 26th. The stock was sold at an average price of $517.28, for a total value of $4,914,160.00. Following the sale, the chief executive officer owned 324,443 shares in the company, valued at approximately $167,827,875.04. The trade was a 2.84% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Paul A. Mahon sold 8,300 shares of the stock in a transaction dated Thursday, August 20th. The stock was sold at an average price of $523.14, for a total value of $4,342,062.00. Following the transaction, the executive vice president directly owned 45,172 shares in the company, valued at approximately $23,631,280.08. The trade was a 15.52% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 424,075 shares of company stock valued at $227,336,485 over the last ninety days. Insiders own 8.60% of the company’s stock.

United Therapeutics Stock Performance

NASDAQ:UTHR opened at $527.91 on Friday. The stock has a market capitalization of $22.64 billion, a P/E ratio of 18.89, a PEG ratio of 1.75 and a beta of 0.59. The company has a 50 day moving average price of $530.89 and a 200 day moving average price of $538.86. United Therapeutics Corporation has a fifty-two week low of $302.19 and a fifty-two week high of $609.35.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.86 by $0.41. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.The company had revenue of $783.30 million for the quarter, compared to analyst estimates of $804.65 million. During the same quarter in the previous year, the company earned $6.41 earnings per share. The firm’s quarterly revenue was down 1.9% compared to the same quarter last year. Research analysts forecast that United Therapeutics Corporation will post 26.33 earnings per share for the current fiscal year.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.